NCT05186922View on ClinicalTrials.gov

The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
Moderate-to-severe Atopic Dermatitis
Interventions
BIOLOGICAL

CM326

CM326 injection

OTHER

Placebo

Placebo

Trial Locations (1)

Unknown

RECRUITING

Peking University People's hospital, Beijing

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY